The Centers for Medicare & Medicaid Services (CMS) released a national policy regarding coverage for Aduhelm (aducanumab). Controversy has surrounded the Alzheimer’s drug Aduhelm from Biogen (NSDQ:BIIB) and Eisai (TYO:4523) since the FDA’s fast track approval last year. Three members of an FDA advisory committee resigned after the approval. About a week later, nonprofit watchdog group Public Citizen called for high-profile resignations of…
How direct-to-patient can impact pharma supply chains
In the wake of COVID-19, telemedicine has become the only means for delivering patient care for many physician groups. As healthcare providers adapted to treating patients virtually, patients likewise adapted to disrupted routines. For those dependent on prescription medication to treat or manage a medical condition, “going to the pharmacy” was an errand replaced by…
Trump’s ‘most-favored nation’ drug-pricing plan hits a snag
A federal judge in Maryland has temporarily blocked a Trump executive order that tied Medicare reimbursement for several drugs to lower rates in other countries. The executive order was facing a flurry of lawsuits. U.S. District Judge Catherine C. Blake sided with the plaintiffs’ argument that the Department of Health and Human Services (HHS) did not…